News
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
25 Apr 24
Short Sellers, Short Ideas, Trading Ideas
Vertex Announce Licensing Agreement And Collaboration With Treefrog Therapeutics To Optimize Production Of Vertex's Cell Therapies For Type 1 Diabetes
23 Apr 24
News
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
18 Apr 24
News, Price Target, Small Cap, Markets, Analyst Ratings, Trading Ideas
Vertex Pharmaceuticals Announced Advancements Across Its Suzetrigine Pain Program For Acute And Neuropathic Pain
18 Apr 24
Biotech, News, Health Care, General
Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450
18 Apr 24
News, Price Target, Analyst Ratings
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today
16 Apr 24
News, Trading Ideas
Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Maintains $500 Price Target
15 Apr 24
News, Price Target, Analyst Ratings
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
12 Apr 24
Analyst Ratings
Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Maintains $371 Price Target
12 Apr 24
News, Price Target, Analyst Ratings
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
11 Apr 24
Analyst Color, Biotech, Equities, Large Cap, M&A, News, Upgrades, Health Care, Price Target, Analyst Ratings, Trading Ideas, General
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
11 Apr 24
Cryptocurrency, Large Cap, Macro Economic Events, Mid Cap, Sector ETFs, Short Sellers, Bonds, Broad U.S. Equity ETFs, Commodities, Treasuries, Top Stories, Economics, Intraday Update, Tech, ETFs
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
11 Apr 24
Biotech, Large Cap, M&A, News, Health Care, Movers, Trading Ideas, General
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $462
11 Apr 24
News, Price Target, Analyst Ratings
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
11 Apr 24
Equities, News, Top Stories, Markets
Evercore ISI Group Upgrades Vertex Pharmaceuticals to Outperform, Announces $438 Price Target
11 Apr 24
News, Upgrades, Price Target, Analyst Ratings
Vertex Subsidiary To Commence Cash Tender Offer To Purchase All Outstanding Shares Of Alpine Common Stock
10 Apr 24
M&A, News
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
9 Apr 24
Long Ideas, M&A, News, Small Cap, Top Stories, Markets, Media, Trading Ideas
Reported Earlier, Vertex Advances Inaxaplin Into Phase 3 Portion Of Adaptive Phase 2/3 Clinical Trial For The Treatment Of APOL1-Mediated Kidney Disease
1 Apr 24
Biotech, News, General
Vertex Announces New Drug Submission For Exagamglogene Autotemcel Has Been Accepted For Priority Review By Health Canada For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia
1 Apr 24
Biotech, News, Global, General
10 Health Care Stocks With Whale Alerts In Today's Session
28 Mar 24
Options
Press releases
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
23 Apr 24
News, Contracts, Press Releases
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
12 Apr 24
Press Releases
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
10 Apr 24
Press Releases
Vertex to Announce First Quarter 2024 Financial Results on May 6
9 Apr 24
Press Releases
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
1 Apr 24
Press Releases
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
News, Press Releases
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
News, Press Releases
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
25 Mar 24
News, Press Releases
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
22 Mar 24
News, Press Releases
Thinking about trading options or stock in Tesla, Energy Transfer, Paramount Global, Vertex Pharmaceuticals, or Broadcom ?
21 Mar 24
Opinion, Press Releases
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
13 Feb 24
Press Releases
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
5 Feb 24
Press Releases
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
5 Feb 24
Press Releases
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
5 Feb 24
Opinion, Press Releases
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
30 Jan 24
Press Releases